EGFR and lung cancer: Amplification of wildtype MET in the setting of EGFR mutant lung cancer was one of the earliest examples of this type of mechanism of resistance.25–27 Mutant EGFR heterodimerizes with ErbB-3 to activate the PI3K/Akt signaling pathway.